Spots Global Cancer Trial Database for Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors
Official Title: A Phase I/IIa Study to Evaluate the Safety, Tolerability and Efficacy of IBC0966 in Patients With Advanced Malignant Tumors
Study ID: NCT04980690
Conditions
Interventions
Study Description
Brief Summary: This is a phase I/IIa study to evaluate the safety, tolerability and efficacy of IBC0966 for the treatment of subjects with advanced malignant tumors.
Detailed Description: The study includes three phases: dose escalation (Phase Ia), dose extension (Phase Ib), and clinical exploration (Phase IIa). First, the Phase Ia dose escalation will be carried out. After switching to the 3+3 escalation mode, the Phase Ib dose extension study can be carried out at the same time. After Phase Ia is completed and RP2D is obtained, Phase IIa clinical exploratory research can be carried out.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Affiliated Tumor Hospital of Harbin Medical University, Harbin, Heilongjiang, China
Contact Details
Name: Qingyuan Zhang
Affiliation: The Affiliated Tumor Hospital of Harbin Medical University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
